Furthermore, FGFR1 inhibition has shown efficacy in pre-clinical in vitro and in vivo MCL models (33), suggesting that FGFR1 may become a therapeutic target in this type of lymphoma, even without evidence of overt transdifferentiation. This evidence concerns the gene FGFR1 and lymphoma.